AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04638049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
Study NCT04460066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-L1 antibody
Description: Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
Study NCT04460066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin bound paclitaxel
Description: Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
Study NCT04460066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albumin bound paclitaxel
Description: Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
Study NCT04460066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
Study NCT04460066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
Study NCT04460066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
Study NCT04460066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical resection of esophageal carcinoma
Description: Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
Study NCT04460066 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: radical resection of esophageal carcinoma
Description: Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
Study NCT00653185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study NCT00653185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study NCT00653185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study NCT00653185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study NCT04236440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B2)
Description: 80 μg BAY2586116 (nasal spray)
Study NCT02042248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
Study NCT03359447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Ferrous Sulfate
Description: Drops
Study NCT00653185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study NCT04412122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
Study NCT04412122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping+Breathing Exercise
Description: In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
Study NCT04412122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention was performed to reduce pain in the control group.
Study NCT03340259 — intervention group
Intervention type: PROCEDURE
Intervention: Exposure(s) of interest: enterostomy
Description: Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
Study NCT02997410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Study NCT02997410 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Ozone)
Study NCT02997410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental treatment with occlusal splint
Study NCT02693288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration anesthesia
Description: Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
Study NCT02848625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
Study NCT03359447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily Ferrous Sulfate
Description: Drops
Study NCT04006301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-74699157
Description: Participants will receive JNJ-74699157 orally.
Study NCT00703352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone (coated tablet) 50mg daily during 12 months.
Study NCT00703352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone (coated tablet) 50mg daily during 12 months.
Study NCT02196610 — intervention group
Intervention type: OTHER
Intervention: Applanation tonometry
Description: Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CRN01941 Oral Solution
Description: Investigational drug
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN01941 Oral Solution
Description: Investigational drug
Study NCT02158104 — intervention group
Intervention type: PROCEDURE
Intervention: Deep dry needling
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CRN01941 Oral Capsule
Description: Investigational drug
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand cigarette
Description: Smoke, 15 puff of, Own Brand cigarettes;
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one high 2,4% nicotine
Description: Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN01941 Oral Capsule
Description: Investigational drug
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study NCT01873053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-34B
Description: Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
Study NCT01873053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01144260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bafetinib
Description: 250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
Study NCT02526862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allevyn Thin®
Description: Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
Study NCT02526862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Askina Transorbent Border®
Description: Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
Study NCT02526862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linovera®
Description: Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
Study NCT03173911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage
Description: Application of Elastic Bandage Therapy by the Therapy Taping method
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: original 7,4 mg nicotine
Description: Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Placebo
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Solution
Description: Placebo
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo
Study NCT01862341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANMUM In-Shape Nutritional Milk Powder for Active Mothers
Study NCT03166579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
Study NCT04236440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (B3)
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril)
Study NCT01243684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTI - Diffusor Tensor Imaging
Description: Radiology intervention
Study NCT01243684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTI - Diffusor Tensor Imaging
Description: Radiology intervention
Study NCT04236440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116 (C)
Description: 160 μg BAY2586116 (pharyngeal spray with direct endoscopic application via a nostril). It is the same procedure as described under part B3.
Study NCT04290143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment (colored tap water)
Description: Patients will be treated with colored tap water for 20 minutes.
Study NCT04015310 — intervention group
Intervention type: DEVICE
Intervention: Quantitative Multi parametric MRI and enhanced MRCP
Description: Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
Study NCT03677583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duckweed
Description: various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
Study NCT03677583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinach
Description: various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nicotine free
Description: smoke, 15 puff, of electronic cigarette nicotine free
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study NCT01665066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ego 9mg
Description: smoke, 15 puff, of electronic cigarette Ego 9 mg
Study NCT04730245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phosphate enema, oral rifaximin and polyethylene glycol
Description: Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study
Study NCT00796055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-547
Description: Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
Study NCT04208750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision R-800 Phoropter
Description: Refraction utilizing the Vision R-800 Phoropter with resulting glasses
Study NCT04208750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vision R-800 Phoropter
Description: Refraction utilizing the Vision R-800 Phoropter with resulting glasses
Study NCT04208750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Phoropter
Description: Refraction utilizing the standard phoropter with resulting glasses
Study NCT04208750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Phoropter
Description: Refraction utilizing the standard phoropter with resulting glasses
Study NCT01555697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study NCT01555697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study NCT05927597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS1007
Description: Oral tablets.
Study NCT05927597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets.
Study NCT02466841 — intervention group
Intervention type: PROCEDURE
Intervention: Cubital tunnel release
Description: Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
Study NCT00527020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1018921
Description: GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
Study NCT03936166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo
Study NCT00527020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Lozenges
Description: Nicotine Lozenges will be supplied as 4 milligrams lozenges.
Study NCT00527020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be given to the subjects.
Study NCT01056120 — intervention group
Intervention type: DEVICE
Intervention: Pro Kinetic Energy bare metal stent
Description: PCI
Study NCT01536704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (2 mg)
Description: 2 mg nicotine lozenge in two formulations
Study NCT01536704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Description: 2 mg nicotine lozenge in two formulations
Study NCT03990103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: 80-120 mg/day, PO, D1-14, every 21 days
Study NCT03990103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: 80-120 mg/day, PO, D1-14, every 21 days
Study NCT03990103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
Study NCT03990103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 200 mg, IP, D1, every 21 days
Study NCT03990103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2, IV, D1, every 21 days
Study NCT05326360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron Hydrochloride
Description: we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
Study NCT00343915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B (thiomersal-free) 20µg
Description: In the primary study: 2 deep intramuscular injections (Months 0, \& 6)
Study NCT00343915 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 μg Engerix™-B (preservative-free)
Description: In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)
Study NCT00343915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: In the primary study: 1 deep intramuscular injection (month 1)
Study NCT04913701 — intervention group
Intervention type: OTHER
Intervention: Observation group 1
Description: Subjects will be followed with 3 swabs and serological test
Study NCT02212171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIAP
Description: The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~1. Administrative staff:~   Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~2. Nursing staff:~   They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~3. GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc.